Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-23
    E.g., 2018-10-23

Archive Search

2 results
12:00 AM, Nov 04, 2013  |  BC Week In Review | Clinical News  |  Clinical Status

RG7314: Phase II started

3Q13 earnings that it began a double-blind, placebo-controlled Phase II trial to evaluate daily oral RG7314
in about 150 patients with ASD. In stage I, patients will receive 1.5 mg RG7314 for …
receive 1.5 or 4 mg for 12 weeks. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland   Product: RG7314
12:00 AM, Feb 04, 2013  |  BC Week In Review | Clinical News  |  Clinical Status

RG7314: Phase I started

its 4Q12 earnings that it began a Phase I trial to evaluate multiple doses of RG7314
of risperidone in up to 24 healthy volunteers. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland   Product: RG7314